Literature DB >> 2437140

Secretion of glycoprotein hormone alpha-subunit by pituitary tumors.

M Ishibashi, T Yamaji, F Takaku, A Teramoto, T Fukushima.   

Abstract

Serum glycoprotein hormone alpha-subunit levels were determined in 165 patients with pituitary adenomas. Elevated serum alpha-subunit levels were found in 17 patients (acromegaly, 5 of 58; prolactinoma, 6 of 56; nonfunctioning adenoma, 5 of 32; and ACTH-producing adenoma, 1 of 19), most of whom had normal serum TSH and gonadotropin levels. When TRH (0.5 mg) was injected iv in the 6 prolactinoma patients with elevated serum alpha-subunit levels, serum PRL and alpha-subunit levels increased in only 1 patient. Four acromegalic patients with high serum alpha-subunit levels received TRH; serum GH and alpha-subunit increased in 1 patient and did not change in 2, and only serum GH increased in the remaining patient. Oral administration of bromocriptine (5 mg), on the other hand, consistently decreased serum alpha-subunit and PRL levels in 2 patients with prolactinoma and alpha-subunit and GH levels in 1 acromegalic patient. When serum from 3 patients was subjected to Sephadex G-100 gel filtration, immunoreactive alpha-subunit eluted in a single peak, which emerged in fractions corresponding to [125I]TSH alpha. Concanavalin A (Con A) affinity chromatography revealed that the major portion of immunoreactive alpha-subunit was retained to Con A. A pituitary adenoma removed at surgery from a patient with acromegaly was studied in monolayer cell culture. Secretion of both alpha-subunit and GH from cultured adenoma cells was stimulated by TRH and suppressed by dopamine in a dose-dependent manner. Immunohistochemistry of the pituitary adenomas removed from patients with prolactinoma and acromegaly who had high serum alpha-subunit levels demonstrated alpha-subunit-containing cells as well as PRL- or GH-containing cells. These results suggest that elaboration of glycoprotein hormone alpha-subunit occurs without concurrent production of glycoprotein hormones in a substantial number of patients with pituitary adenomas and that alpha-subunit responses to stimuli in such adenomas are generally parallel with those of the concomitantly produced hormones.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437140     DOI: 10.1210/jcem-64-6-1187

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

Review 2.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Fluorescence histochemistry of RNA in human pituitary adenomas.

Authors:  H B Sarnat; J H García; B Curry
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Gonadotrophin and free alpha-subunit secretion in patients with acromegaly and clinically non-functioning pituitary tumors: anterior pituitary function and the effect of thyrotrophin-releasing hormone.

Authors:  S S Damjanović; V P Popović; M S Petakov; M M Nikolic-Durović; M Z Doknić; M S Gligorović
Journal:  J Endocrinol Invest       Date:  1996-11       Impact factor: 4.256

5.  Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas.

Authors:  M C Vantyghem; C Cortet; C Bauters; M H Gevaert; D Dewailly; J Lefebvre; M Mazzucca
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

6.  Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.

Authors:  C Blanco; T Lucas; J Alcañiz; N Davila; P Serrano; B Barcelò; J Estrada
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.